摘要
目的观察老年慢性心力衰竭(CHF)患者采用托拉塞米联合参脉注射液治疗的临床效果。方法选取2017年6月至2018年12月大庆龙南医院治疗的88例CHF患者,将其分为两组,每组44例。对照组按照常规治疗方案进行治疗;观察组在对照组治疗基础上联合托拉塞米与参脉注射液治疗。比较两组治疗有效率及血管紧张素(Ang)-Ⅱ、醛固酮(ALD)、肾素活性(PRA)水平,左心室舒张期内径(LVDd)、左室射血分数(LVEF)、心室短轴缩短率(FS)指标变化情况。结果观察组治疗有效率为95.45%(42/44),对照组为79.55%(35/44),差异有统计学意义(χ~2=5.09,P<0.05)。治疗后,观察组患者的Ang-Ⅱ、ALD、PRA水平均明显低于对照组,差异有统计学意义(P<0.05);观察组患者的LVDd明显小于对照组,LVEF、FS明显高于对照组(P<0.05)。结论对老年CHF患者采取托拉塞米联合参脉注射液治疗可改善患者左心室结构及功能,抑制肾素-血管紧张素-醛固酮系统(RAAS)激活,提高整体疗效,应用效果显著。
Objective To observe the clinical effect of torasemide combined with Shenmai Injection on the elderly patients with chronic heart failure(CHF).Methods Eighty-eight CHF patients treated in Daqing Longnan hospital from June 2017 to December 2018 were divided into two groups,with 44 cases in each group.The control group was treated according to the conventional treatment plan;the observation group was treated with torasemide and Shenmai Injection on the basis of the control group.The therapeutic efficacy,Ang-Ⅱ,ALD,PRA,left ventricular diastolic diameter(LVDD),left ventricular ejection fraction(LVEF),and ventricular short axis shortening rate(FS)were compared between the two groups.Results The effective rate was 95.45%(42/44)in the observation group and 79.55%(35/44)in the control group,the difference was significant(χ~2=5.09,P<0.05).After treatment,the levels of Ang-Ⅱ,ALD and PRA in the observation group were significantly lower than those in the control group(P<0.05);the level of LVDd in the observation group was significantly lower than that in the control group,and the levels of LVEF and FS were significantly higher than those in the control group(P<0.05).Conclusions Torasemide plus Shenmai injection can improve the structure and function of left ventricle in elderly patients with CHF,inhibit RAAS activation,improve the overall effect,and the application effect is significant.
作者
邓庆梅
Deng Qingmei(Department of Geriatrics,Longnan Hospital of Daqing,Daqing 163453,China)
出处
《临床医学》
CAS
2020年第1期117-119,共3页
Clinical Medicine
